Robalzotan
Chemical compound
From Wikipedia, the free encyclopedia
Robalzotan (INN, BAN; developmental code names NAD-299, AZD-7371) is a selective antagonist at the serotonin 5-HT1A receptor which was under development for the treatment of major depressive disorder, anxiety disorders, gastrointestinal disorders, irritable bowel syndrome (IBS), and overactive bladder.[2][3][4][5]
- None
| Clinical data | |
|---|---|
| Other names | NAD-299; NAD299; AZD-371; AZD371 |
| Routes of administration | Oral[1] |
| Drug class | Serotonin 5-HT1A receptor antagonist |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C18H23FN2O2 |
| Molar mass | 318.392 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
It was shown to completely reverse the autoreceptor-mediated inhibition of serotonin release induced by the administration of selective serotonin reuptake inhibitors (SSRIs) like citalopram in rodent studies.[6]
The drug was investigated by AstraZeneca as a potential antidepressant, but like many other serotonin 5-HT1A receptor modulators, was discontinued.[7] Later on, it was also researched for other indications, such as IBS, but was dropped once again due to lack of effectiveness[3] as well as a poor tolerability profile, which included effects such as "hallucinations or hallucination-like adverse events".[1]